Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Core Insights - Tempest Therapeutics, Inc. has successfully closed an all-stock transaction to acquire dual-targeting CAR-T programs and secured financing support from Factor Bioscience Inc., enhancing its portfolio and operational runway [1][4] Group 1: Transaction Details - The transaction includes a diverse portfolio of clinical-stage product candidates and extends the operational runway to mid-2027, supporting multiple potential value-generating milestones [1][4] - The acquisition brings next-generation CAR-T assets, including TPST-2003, a dual-targeting CD-19/BCMA CAR-T, with a biologics license application (BLA) filing in China planned for 2027 [4][5] - The transaction was finalized following stockholder approval of share issuance at the 2025 Annual Meeting on January 27, 2026 [4] Group 2: Leadership Changes - Dr. Matt Angel has joined Tempest as President and CEO, expressing excitement about developing the innovative pipeline for treating solid tumors and hematologic malignancies [2][4] - Stephen Brady, Chair of the Board, acknowledged the contributions of outgoing board members and emphasized the importance of the transaction for the company's financial stability and future milestones [2][3] Group 3: Pipeline Developments - Amezalpat (TPST-1120) is ready for Phase 3 trials in first-line liver cancer, supported by global regulatory agreement and positive Phase 2 data [5] - TPST-2003 has completed Phase 1 trials in patients with relapsed/refractory multiple myeloma, with data expected in 2026 and a BLA in China planned for 2027 [5] - Tempest plans to initiate a Phase 2 study of TPST-1495 in familial adenomatous polyposis (FAP) in Q1 2026, funded by the National Cancer Institute [5][11]